Replies to post #35016 on Relief Therapeutics Holding AG (RLFTF)

[rollup]

..... and what does this report confirm about Eli Lilly's bamlanivimab and Regeneron's cocktail!
At best with caution for emergencies among many other difficulties! READ report --- not positive.

Today's report on the inhaler study has discreetly confirmed a much more important message for us! ------ "ZYESAMI ™ is a synthetic form of human Vasoactive Intestinal Peptide (VIP). Emerging data indicate that the drug protects the alveolar type II cells upon which the lung depends on the production of surfactant and which are the primary target of the SARS-CoV-2 Coronavirus.

[Vader69]

I’ve used bamlanivimab. Can confirm it’s worthless. It is not a concern for investors and has no efficacy like the initial EAP data and clearing chest xrays suggest w/ VIP. Holding for top line data.